|Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome.|
|Jump to Full Text|
|PMID: 20040816 Owner: NLM Status: PubMed-not-MEDLINE|
|Results of the PROWESS trial suggested that heparin may reduce the efficacy of recombinant human activated protein C (rhAPC) and the XPRESS study also showed increased bleeding complications in patients receiving heparin with rhAPC. Although it has been shown that heparin prophylaxis may be used along with rhAPC, no study has shown the interaction between continuous heparin infusion and rhAPC. Here, we report a case of severe sepsis with pulmonary embolism who was concurrently administered heparin and rhAPC infusions, with positive results and no bleeding complications.|
|Deven Juneja; S Mohan; Vivek V Veturi; Palepu B Gopal|
Related Documents :
|20040816 - Concurrent administration of heparin and activated protein c in a patient with pulmonar...
19332856 - Pulmonary cement embolism after percutaneous vertebroplasty in osteoporotic vertebral c...
10744146 - Value of chest x-ray combined with perfusion scan versus ventilation/perfusion scan in ...
23769556 - Value of ct pulmonary arteriography and venography in the evaluation of venous thromboe...
12414036 - Drainage patterns of middle lobe vein of right lung: an anatomical study.
6858926 - Subcostal 2-dimensional echocardiographic imaging of peripheral left coronary artery an...
|Type: Journal Article|
|Title: Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine Volume: 13 ISSN: 1998-359X ISO Abbreviation: Indian J Crit Care Med Publication Date: 2009 Jul-Sep|
|Created Date: 2009-12-30 Completed Date: 2010-06-16 Revised Date: 2010-09-28|
Medline Journal Info:
|Nlm Unique ID: 101208863 Medline TA: Indian J Crit Care Med Country: India|
|Languages: eng Pagination: 163-6 Citation Subset: -|
|Department of Anesthesia and Critical Care Medicine, Global Hospital, Lakdi-ka-pul, Hyderabad, India. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): Indian J Crit Care Med
Journal ID (publisher-id): IJCCM
Publisher: Medknow Publications, India
? Indian Journal of Critical Care Medicine
Print publication date: Season: Jul?Sep Year: 2009
Volume: 13 Issue: 3
First Page: 163 Last Page: 166
Publisher Id: IJCCM-13-163
PubMed Id: 20040816
|Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome|
|Vivek V. VeturiAF0001|
|Palepu B. GopalAF0001|
From: Department of Anesthesia and Critical Care Medicine, Global Hospital, Lakdi-ka-pul, Hyderabad, India
|Correspondence: Correspondence: Dr. Deven Juneja, Room No. 215, Department of Anesthesia and Critical Care, Global Hospital, Lakdi-ka-pul, Hyderabad - 500 004, India. E-mail: firstname.lastname@example.org
Severe sepsis (SS) is the commonest cause of mortality in the intensive care. Several biological products with anticoagulant activity have been tested in clinical trials as complementary treatment for septic patients. However, recombinant human activated protein C (rhAPC) is the only one which has shown to reduce mortality in SS and has been recommended in patients at high risk of death and no absolute contraindication related to bleeding risk or relative contraindication that outweighs the potential benefit.[2?5] The phase 3 trial assessing the efficacy of rhAPC, the PROWESS Trial, had excluded the patients who required anticoagulation for a documented or suspected deep-vein thrombosis (DVT) or pulmonary embolism (PE) due to increased risk of bleeding complications. It also raised the possibility that heparin might reduce the efficacy of rhAPC as the risk reduction due to rhAPC was less in the group of patients exposed to heparin. A further trial, the XPRESS study, showed that heparin for DVT prophylaxis does not reduce the efficacy of rhAPC, and hence it should be continued when rhAPC is started in the event of the patient developing sepsis. No study has shown the effect of continuous heparin infusion on rhAPC or vice versa. Here, we report a case of SS with pulmonary embolism who was concurrently administered heparin and rhAPC infusions with positive results.
A 49-year-old hypertensive, non-diabetic male patient who was a known case of bilateral osteoarthritis of the knees, was admitted for bilateral total knee replacement. The patient was on Atenolol 100 mg and Ecosprin 50 mg preoperatively.
Surgery was uneventful, and he was transferred to a surgery ward after one day observation in the surgical intensive care unit (ICU) with an opioid epidural analgesia. DVT prophylaxis with low molecular weight heparin (LMWH) was started after surgery. On the third postoperative day, he developed sudden onset of breathlessness and dizziness associated with fever, hypotension and oxygen desaturation. However, there was no tachypnea, and the lungs were clear on auscultation. Dopamine infusion was started, and epidural opioids were stopped when the patient remained hypotensive even after fluid challenge; the patient was subsequently shifted to the ICU.
In the ICU, a central line was inserted, central venous pressure was recorded (13-14 mm Hg), nor-adrenaline was started and dopamine was stopped. Chest X-ray was normal, and arterial blood gases revealed a pH of 7.382, PaO2 of 94 mmHg (12.5 kPa), PaCO2 of 19 mmHg (2.5 kPa), and base deficit of 14 mEq/L on 10 L/min of oxygen through face mask. Electrocardiography showed S1Q3T3 pattern [Figure 1] and 2D Echo revealed plethoric inferior vena cava with mildly dilated right atrium and ventricle. D-Dimer was highly positive, but bilateral leg vein Doppler was negative for DVT. Because of high probability of PE, a CT pulmonary angiogram was performed, which revealed filling defects in the right lower lobe segmental artery with bilateral pleural effusion [Figure 2].
Patient was immediately started on heparin infusion at 1000 IU/h (14 IU/kg/h). Laboratory values are given in Table 1.
The patient continued to deteriorate with progressive hypotension, increased need for vasopressors and oxygen support, with reduced urine output. Heparin was increased to 1200 IU/h (17 IU/kg/h). Synovial fluid culture from knees grew MRSA, and hence, the antibiotics were changed from ciprofloxacin to piperacillin with tazobactam and linezolid in view of associated severe sepsis although blood cultures were negative.
On the fifth postoperative day, patient had to be intubated and put on mechanical ventilation due to worsening hypoxia on non-invasive ventilation. The epidural catheter was removed. For progressive hypotension, dopamine, dobutamine and vasopressin were sequentially added along with a low dose steroid. He became anuric and hence was started on continuous renal replacement therapy (CRRT). In view of SS with multi-organ failure (APACHE II score - 26), rhAPC was started (24 mcg/kg/h) and heparin infusion was continued. The dose of heparin was adjusted according to activated partial thromboplastin time (APTT) levels even if it meant increasing the dose beyond 15 units/kg/h, which is generally recommended as the maximum limit for a patient on rhAPC (Xigris information booklet).
Forty-eight hours after starting rhAPC, the patient started to show gradual improvement in oxygenation and blood pressure. Vasopressors were slowly tapered off over the next 3 days. There were no signs of bleeding anywhere or significant thrombocytopenia while heparin and rhAPC infusions were continued. On the eighth postoperative day, the patient was extubated onto noninvasive ventilatory support.
On the ninth postoperative day, CRRT was stopped as the patient started to produce urine. rhAPC was stopped after 96 h infusion.
On the 11th postoperative day, a repeat CT pulmonary angiogram was performed which showed complete resolution of the embolus. Hence, heparin was stopped and the patient was maintained on LMWH and oral anticoagulation- (acitrom - acenocoumarol). Intermittent dialysis was also discontinued as the patient's renal parameters improved and his urine output was adequate. The patient was subsequently transferred to the surgery ward. His further hospital stay was uneventful, and he was discharged from the hospital on the 15th postoperative day.
Septic patients are at increased risk of venous thromboembolic events, which may be due to advanced age, chronic cardiopulmonary disease, recent surgery, immobilization, or in-dwelling vascular catheters. Even though the concurrent use of heparin and APC is not contraindicated in such patients and heparin prophylaxis has been recommended even if a patient is on rhAPC, rhAPC has to be used with caution and the heparin dose should be less than 15 IU/kg/h (Xigris information booklet). To the best of our knowledge, no other case has been reported with concurrent use of heparin infusion and rhAPC.
Sepsis is characterized by a systemic inflammatory and procoagulant response to infection. The rationale behind anticoagulant treatments is that certain factors such as APC, antithrombin (AT) and Tissue Factor Pathway Inhibitor (TFPI) are depleted, and the use of recombinant technology may replenish them.[2?5] Although heparin does not replenish what sepsis patients have depleted, it binds to and activates AT which reduces thrombin generation and fibrin formation, which may help in combating sepsis. Heparin also has many immunomodulatory actions that may affect the systemic response to sepsis. It has been shown in a small cohort study that the early administration of intravenous therapeutic dose of unfractionated heparin may be associated with decreased mortality when administered to patients with septic shock, especially in patients with higher severity of illness.
Earlier data supported the possibility of heparin reducing the efficacy of rhAPC. It was suggested that the activation of protein C in vivo can be blocked by administration of low levels of heparin as heparin leads to the inhibition of thrombin, which is vital for the activation of protein C. Moreover, APC has its own unique inhibitor, the APC inhibitor, which is stimulated by relatively high levels of heparin (5-10 ?/ml).
Recently, heparin and rhAPC have shown significant anticoagulant synergy in plasma due to decreased thrombin generation by the prothrombinase complex. Further, the reduction in sepsis-induced interactions between isolated platelets, neutrophils, and endothelial cells that is caused by rhAPC may be attenuated by low-dose heparin, which may play a role in preserving microvascular patency in patients with septic shock. Emergent data from in vitro studies have also suggested that patients with SS might benefit from a treatment with combinations of anticoagulant agents that might have worked to control sepsis in our patient too.
In addition to heparin, which might have been beneficial in controlling sepsis, rhAPC also might have helped in the treatment of PE in our patient as it has been shown to cause systemic anticoagulation and enhance fibrinolysis by inhibiting plasminogen activator inhibitor activity. rhAPC has also been used in managing acute myocardial infarction patients after thrombolysis.
We did not observe any bleeding complications inspite of giving more than the recommended dose of heparin (up to 17 IU/kg/h) along with rhAPC in our patient, which may be due to the close monitoring of coagulation parameters. Therefore, it seems prudent that rhAPC and heparin can be given concurrently, with positive results, in selected patient groups under close monitoring without any increased risk of bleeding. Moreover, it seems that there may be some cross benefit of using heparin and rhAPC in septic patients with thrombotic complications.
Source of Support: Nil
Conflict of Interest: None declared.
|1.||Angus DC,Linde-Zwirble WT,Lidicker J,Clermont G,Carcillo J,Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCrit Care MedYear: 20012913031011445675|
|2.||Bernard GR,Vincent JL,Laterre PF,LaRosa SP,Dhainaut JF,Lopez-Rodriguez A,et al. Efficacy and safety of recombinant human activated protein C for severe sepsisN Engl J MedYear: 200134469970911236773|
|3.||Eisele B,Lamy M,Thijs LG,Keinecke HO,Schuster HP,Matthias FR,et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsisIntensive Care MedYear: 199824663729722035|
|4.||Zarychanski R,Doucette S,Fergusson D,Roberts D,Houston DS,Sharma S,et al. Early intravenous unfractionated heparin and mortality in septic shockCrit Care MedYear: 2008362973918824906|
|5.||Abraham E,Reinhart K,Opal S,Demeyer I,Doig C,Rodriguez AL,et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trialJAMAYear: 20032902384712851279|
|6.||Levi M,Levy M,Williams MD,Douglas I,Artigas A,Antonelli M,et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)Am J Respir Crit Care MedYear: 20071764839017556722|
|7.||Robertson MS. Heparin: The cheap alternative for immunomodulation in sepsis?Crit Care ResuscYear: 20068235816930112|
|8.||Comp PC. Heparin-protein C interactionNouv Rev Fr HematolYear: 198426239426089102|
|9.||Pet?j? J,Fern?ndez JA,Gruber A,Griffin JH. Anticoagulant synergism of heparin and activated protein C in vitroRole of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated proteinYear: 199799265563|
|10.||Kirschenbaum LA,Lopez WC,Ohrum P,Tsen A,Khazin J,Astiz ME. Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shockCrit Care MedYear: 20063422071216775572|
|11.||Cimenti C,Koestenberger M,Leschnik B,Haidl H,Muntean W. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CATThromb ResYear: 2007119361716712904|
|12.||Sakamoto T,Ogawa H,Takazoe K,Yoshimura M,Shimomura H,Moriyama Y,et al. The effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: Comparison with unfractionated heparinJ Am Coll CardiolYear: 20034213899414563580|
Test parameters of the patient along with heparin, activated protein C and continuous renal replacement therapy support
|Parameter of interest||Pre-op||1st PO day||3rd PO day||4th PO day||5th PO day||6th PO day||7th PO day||8th PO day||9th PO day||10th PO day|
|Platelets, ? 1011/L||2.47||1.37||2.08||1.79||1.45||1.05||0.97||0.84||0.37||0.27|
|TLC, per mm3||7700||4900||11200||7800||16600||17100||12200||12200||11600||12100|
PO - Postoperative; APTT - Activated partial thromboplastin time; INR - International normalized ratio, TLC - Total leukocyte count; APC - Activated protein C; and CRRT - Continuous renal replacement therapy
Keywords: Activated protein C, heparin, pulmonary embolism, severe sepsis.
Previous Document: How correct is the correct length for central venous catheter insertion.
Next Document: Vincristine-induced acute life-threatening hyponatremia resulting in seizure and coma.